Abstract:Ovarian cancer (OC) is the second most common form of gynecological cancer and is the most fatal among all forms of gynecological malignancies. Despite the important role of metabolic processes in the molecular pathogenesis of OC, robust metabolic markers to enable effective screening, rapid diagnosis, accurate surveillance, and therapeutic monitoring of OC are still lacking. In this study, we present a targeted liquid chromatography‐tandem mass spectrometry (LC‐MS/MS)‐based metabolic profiling approach for the identification of metabolic biomarker candidates that could enable expedited, highly sensitive and specific OC detection. Using this targeted approach, 90 plasma metabolites from many metabolic pathways of potential biological significance were reliably detected and monitored in 218 samples taken from the three groups of subjects (78 OC patients, 50 benign samples, and 90 healthy controls). Multivariate significance testing and receiver operating characteristic (ROC) analysis revealed 8 significant metabolites (p<0.05) with high magnitudes of fold change (FC>2) and high predictive accuracy [area under the curve (AUC)>0.90] for distinguishing healthy controls from OC patients. For discrimination of OC patients from benign samples, the results of our model refinement pipeline informed the construction of a logistic regression classifier defined by a 5‐metbaolite panel of potential plasma biomarkers, exhibiting roughly 75% predictive accuracy using a 50% random‐split training and testing paradigm for external validation. Multivariate ROC analysis showed enhanced classification performance for identification of OC patients from benign samples, relative to individual metabolites. Pathway analysis revealed significant disturbances in glycine, serine, and threonine metabolism; glyoxylate and dioxylate metabolism; the pentose phosphate pathway; and histidine metabolism. The results expand basic knowledge of the metabolome related to OC pathogenesis relative to both healthy and benign samples, revealing potential pathways or markers that can be targeted therapeutically. This study also provides a promising basis for the development of larger multi‐site projects to validate our findings across population groups and further advances the development of improved clinical care for OC patients.

Metabolomic biomarkers for benign conditions and malignant ovarian cancer: Advancing early diagnosis

Ovarian Cancer Detection Using Targeted Plasma Metabolic Profiling

Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer.

Untargeted Metabolomic Characterization of Ovarian Tumors

Profiling the Metabolome of Uterine Fluid for Early Detection of Ovarian Cancer.

Discrimination Between Malignant and Benign Ovarian Tumors by Plasma Metabolomic Profiling Using Ultra Performance Liquid Chromatography/Mass Spectrometry

Urinary Hydrophilic and Hydrophobic Metabolic Profiling Based on Liquid Chromatography-Mass Spectrometry Methods: Differential Metabolite Discovery Specific to Ovarian Cancer

Identification of Metabolic Biomarkers to Diagnose Epithelial Ovarian Cancer Using A Uplc/Qtof/Ms Platform

A Multiplex Methylation-Specific Pcr Assay For Detection Of Early-Stage Ovarian Cancer Using Cell-Free Serum Dna

Protocol for Identifying Metabolite Biomarkers in Patient Uterine Fluid for Early Ovarian Cancer Detection

Identi Fi Cation of Potential Biomarkers for Ovarian Cancer by Urinary Metabolomic Pro Fi Ling

Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass

Screening and Verifying Endometrial Carcinoma Diagnostic Biomarkers Based on a Urine Metabolomic Profiling Study Using UPLC-Q-TOF/MS.

Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS)

Serum lipid profiling analysis and potential marker discovery for ovarian cancer based on liquid chromatography–Mass spectrometry

Lipid metabolites abnormally expressed in pelvic fluid as potential biomarkers for ovarian cancer: A case-control study

Metabolic Phenotyping for Monitoring Ovarian Cancer Patients

Expanded metabolomics approach to profiling endogenous carbohydrates in the serum of ovarian cancer patients.

Differential plasma lipids profiling and lipid signatures as biomarkers in the early diagnosis of ovarian carcinoma using UPLC-MS

Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.

Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids